1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Oxygenta Pharmaceutical Limited

Oxygenta Pharmaceutical Limited

BBSE:OXYGENTAPH
47.00
INR
-0.19
(-0.40%)
-3.66EPS
1.79BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2.42
6.12
12.18
7.99
12.62
20.1
13.44
51
47.49
21.82
12.37
30.41
30.55
36.31
Basic EPS, GAAP
-4.2
-5.99
-5.39
-5.69
-4.44
-3.19
-5.67
2.87
-0.48
-8.15
-1.09
-2.86
-4.75
-3.66
Free Cash Flow per Basic Share
-2.64
-4.2
0.83
0.51
1.26
-7.64
-3.05
-8.2
-5.2
-7.94
-5.35
-2.38
-10.98
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-9.09
-15.75
-21.14
-26.84
-31.28
-34.47
-40.14
-37.27
-24.38
-32.53
-6.01
-6.93
-11.54
- -
Tangible Book Value per Share
-9.09
-15.75
-21.14
-26.84
-31.28
-34.47
-40.14
-37.27
-24.38
-32.53
-6.01
-6.93
-11.54
- -
Basic Weighted Avg Shares
10
10
10
10
10
10
10
10
13
14
32
36
37
37
Sales/Revenue/Turnover
25
62
124
82
129
205
137
520
605
310
396
1,093
1,130
1,348
Operating Margin (%)
-175.02
-106.68
-40.15
-70.44
-38.37
-14.93
-64.64
5.09
-0.19
-29.52
-31.14
-11.39
-15.04
-7.48
Depreciation Expense
9
25
8
9
9
10
10
12
16
21
27
36
23
21
Net Income, GAAP
-43
-61
-55
-58
-45
-33
-58
29
-6
-116
-35
-103
-176
-136
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
6.81
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-173.61
-97.96
-44.26
-71.24
-35.18
-15.87
-42.2
5.63
-1.01
-37.34
-8.78
-9.42
-15.55
-10.07
Working Capital
-105
-103
-66
-114
-154
-92
-102
-16
15
-79
-96
-549
-347
- -
LT Debt
106
143
171
185
180
209
254
450
510
623
490
215
753
- -
Total Equity
-93
-161
-216
-274
-319
-352
-409
-380
-346
-462
-201
-256
-427
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-531.12
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-220.24
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
343
- -
LT Borrowings
- -
753
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
2,063
1,789
1,793

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
514
- -
Cash, Cash Equivalents & STI
- -
21
- -
Accounts Receivable, Net
- -
100
- -
Inventories
- -
294
- -
Total Current Liabilities
- -
861
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
343
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.49%
12.39%
66.48%
Free Cash Flow
-6.5%
85.17%
374.39%
Net Income, GAAP
175.4%
374.26%
70.63%
Sales/Revenue/Turnover
50.35%
34.91%
3.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
126
140
332
495
1,093
2026
151
143
339
496
1,130
2027
370
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.39
-0.81
-1.07
-0.6
-2.86
2026
-1.65
-1.33
-1.32
-0.45
-4.75
2027
-0.57
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Prasad Reddy Battinapatla
Full Time Employees
170
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No: 43 Hyderabad TS India 500037
IPO Date
Jul 25, 1994
Website
oxygentapharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Oxygenta Pharmaceutical Ltd is an Indian pharmaceutical company specializing in the manufacture and sale of bulk drugs, active pharmaceutical ingredients (APIs), and pharmaceutical preparations including medical and veterinary products. Its main product portfolio encompasses antihypertensive drugs, anticancer drugs, antiulcer drugs, antiretroviral drugs, antiviral drugs, and intermediates such as losartan potassium and gabapentin. The company provides regulatory services, containment solutions, and supplies a range of APIs and excipients, positioning itself as a key player within the pharmaceutical supply chain. Founded in 2011 and headquartered in Telangana, India, Oxygenta operates primarily within the Indian pharmaceutical market. In recent strategic developments, Oxygenta Pharmaceutical underwent significant management changes in 2025 including the resignation of its managing director and other key officers. The company also experienced a promoter shareholding reclassification and attracted investment interest with a notable acquisition of a 28.7% stake by M V S Prasad Reddy in April 2024. Operationally, Oxygenta has continued to expand its manufacturing capabilities and diversified its product range to address complex therapies, with a focus on oncology and chronic disease medications. These changes reflect ongoing efforts to strengthen its market position and expand its operational footprint in India. The company remains listed on the Bombay Stock Exchange, reinforcing its commitment to transparency and market engagement.